perioperative management of anticoagulation...1/18/2016 1 perioperative management of...
TRANSCRIPT
1/18/2016
1
Perioperative Management of Anticoagulation
Rapid Fire Session
Hospital Medicine 2016
San Diego
8 March 2016
Scott Kaatz, DO, MSc, FACP, FHM
Hurley Medical Center
Flint, MI
Associate Professor of Medicine
Michigan State University
• Grant support to institution– Boehringer-Ingelheim– Bristol Myer Squibb– Bayer/Jansen/Johnson and Johnson– Eisai– Iverson Genetics Diagnostics/Medicare – National Institute of Health– Canadian Institute of Health Research– Blue Cross/Blue Shield of Michigan
• Speaker honorarium– Janssen– Boehringer-Ingelheim– Bristol Myer Squibb/Pfizer– CSL Behring– Daiichi Sankyo
• Consultant– Boehringer Ingelheim– Bristol Myer Squibb/Pfizer– Janssen– Daiichi Sankyo– Portola
• Board membership (non-profit)– Thrombosis and Hemostasis Societies of North America– AC Forum– National Certification Board of Anticoagulation Providers– National Blood Clot Alliance Medical and Scientific Advisory Board
Full Disclosure
1/18/2016
2
PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION
• Bridging anticoagulation
– Mechanical valves
– Atrial fibrillation
– Venous thromboembolism
• Anticoagulation reversal
– Warfarin
– Dabigatran
– Rivaroxaban, Apixaban, Edoxaban
• Anticoagulation measurement
4Case
• 76 yo woman with a mechanical mitral valve, chronic atrial fibrillation, and a previous stroke 2 years ago
• To undergo (open) subtotal colectomy for resection of adenocarcinoma of the colon
• What would you do?
A. Don’t interrupt warfarin, perform procedure at therapeutic INR
B. No bridging, hold and restart warfarin only
C. Therapeutic dose UFH or LMWH bridging
D. Prophylactic dose UFH or LMWH bridging
E. Another strategy
1/18/2016
3
5 ACCP Guidelines
Douketis JD. Chest. 2012 Feb;141(2 Suppl):e326S-50S. PMID: 22315266
• 2.4. In patients with a mechanical heart valve, atrial fibrillation, or VTE at high risk for thromboembolism, we suggest• bridging anticoagulation instead of no bridging during interruption
of VKA therapy (Grade 2C)
• In patients with a mechanical heart valve, atrial fibrillation, or VTE at low risk for thromboembolism, we suggest • no bridging instead of bridging anticoagulation during interruption
of VKA therapy (Grade 2C)
• In patients with a mechanical heart valve, atrial fibrillation, or VTE at moderate risk for thromboembolism, • the bridging or no-bridging approach chosen is, as in the higher-
and lower risk patients, based on an assessment of individual patient- and surgery-related factors
6 Risk Stratification for Perioperative Thromboembolism
Douketis JD. Chest. 2012 Feb;141(2 Suppl):e326S-50S. PMID: 22315266
1/18/2016
4
7 Mechanical Heart Valves
a) Starr Edwards – Ball in Cage
b) Medtronic Hall –Single tilting disc
c) St. Jude – Bileaflet tilting disc
d) Carpentier Edwards – Bioprosthetic
e) Hancock -Bioprosthetic
PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION
• Bridging anticoagulation
– Mechanical valves
– Atrial fibrillation
– Venous thromboembolism
• Anticoagulation reversal
– Warfarin
– Dabigatran
– Rivaroxaban, Apixaban, Edoxaban
• Anticoagulation measurement
1/18/2016
5
9
Case
• 78 yo female with AF, HTN, DM on warfarin
• Scheduled for open cholecystectomy
• CHA2DS2-VASc score = 5, CHADS2 = 3
• Would you bridge with therapeutic LMWH?
A. Yes
B. No
10 Risk Stratification for Perioperative Thromboembolism
Douketis JD. Chest. 2012 Feb;141(2 Suppl):e326S-50S. PMID: 22315266
1/18/2016
6
11
BRIDGE Trial• Question: is a strategy of NOT using LMWH
bridging as effective and safer during peri-procedural warfarin interruption in AF?
• Design: RCT• Patients: atrial fibrillation patients undergoing
warfarin interruption for a an invasive procedure or surgery?
• Intervention: dalteparin 100 u/kg q 12 hours bridging
• Control: placebo• Outcome: thromboembolic events and “major”
bleeding• Timeframe: 30 days post procedure
Douketis JD. N Engl J Med. 2015 Aug 27;373(9):823-33. PMID: 26095867
12BRIDGE Trial
Douketis JD. N Engl J Med. 2015 Aug 27;373(9):823-33. PMID: 26095867
1/18/2016
7
13BRIDGE Trial
Douketis JD. N Engl J Med. 2015 Aug 27;373(9):823-33. PMID: 26095867
14BRIDGE Trial
Douketis JD. N Engl J Med. 2015 Aug 27;373(9):823-33. PMID: 26095867
1/18/2016
8
15BRIDGE Trial
Douketis JD. N Engl J Med. 2015 Aug 27;373(9):823-33. PMID: 26095867
Resume LMWH/placebo 24 hours post procedure
Resume LMWH/placebo 48 - 72 hours post procedure
16
Question
• If the CHA2DS2-VASc score = 9, CHADS2 = 6
• Would you bridge with therapeutic LMWH?
A. Yes
B. No
1/18/2016
9
PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION
• Bridging anticoagulation
– Mechanical valves
– Atrial fibrillation
– Venous thromboembolism
• Anticoagulation reversal
– Warfarin
– Dabigatran
– Rivaroxaban, Apixaban, Edoxaban
• Anticoagulation measurement
18Case
• 69 yo with recurrent idiopathic PE, last PE 2 years ago
• Elective hip replacementA. Don’t interrupt warfarin, perform procedure at therapeutic INR
B. No bridging, hold and restart warfarin only
C. Therapeutic dose UFH or LMWH bridging
D. Prophylactic dose UFH or LMWH bridging
E. Another strategy
1/18/2016
10
19 AF Risk Stratification
Douketis JD. Chest. 2012 Feb;141(2 Suppl):e326S-50S. PMID: 22315266
20
VTE (DVT and PE) Bridging
• Design: cohort study
• Patients: 775 with DVT or PE with standard bridging protocol from 1997-2007
• Intervention: 1 of 3 LMWHs
• Comparison: no bridging
• Outcome: thromboembolic and major bleeding events
McBane RD. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):442-8. PMID: 20139361
1/18/2016
11
21
VTE (DVT and PE) Bridging
McBane RD. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):442-8. PMID: 20139361
Proportion Bridged
47/53 = 89%92/111 = 83%360/591 = 61%
22
VTE (DVT and PE) Bridging
• Active cancer was the only independent risk for• Recurrent throboembolism
• Major bleeding
• Death
McBane RD. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):442-8. PMID: 20139361
1/18/2016
12
PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION
• Bridging anticoagulation
– Mechanical valves
– Atrial fibrillation
– Venous thromboembolism
• Anticoagulation reversal
– Warfarin
– Dabigatran
– Rivaroxaban, Apixaban, Edoxaban
• Anticoagulation measurement
24
Case
• 62 yo female with AF, HTN, DM and peripheral vascular disease
• Admitted with severe cellulitis and wet gangrene
• Needs urgent below-knee amputation for infection control
• On warfarin, INR = 4.1, weight 120 kg
• What would you do?
A. Give vitamin K and go to surgery
B. Administer 2 units FFP + vitamin K and go to surgery
C. Administer 3 units FFP + vitamin K and go to surgery
D. Administer 4 units FFP + vitamin K and go to surgery
E. Give 4-factor PCC + Vitamin K and go to surgery
1/18/2016
13
25 Reversal of VKA• Design: RCT, open label
• Patients: Need rapid VKA reversal for surgery/procedure
• Intervention: 4 factor PCC (Kcentra)
• Comparison: FFP
• Outcome: effective haemostasis and rapid INR reduction
Goldstein JN. Lancet. 2015 May 23;385(9982):2077-87. PMID: 25728933
26
Goldstein JN. Lancet. 2015 May 23;385(9982):2077-87. PMID: 25728933
1/18/2016
14
274 Factor PCC vs. FFP for
Urgent Surgery
Goldstein JN. Lancet. 2015 May 23;385(9982):2077-87. PMID: 25728933
28
4 Factor PCC and FFP Dosing
Sarode R. Circulation. 2013 Sep 10;128(11): 1234-43. PMID: 2393511
1/18/2016
15
PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION
• Bridging anticoagulation
– Mechanical valves
– Atrial fibrillation
– Venous thromboembolism
• Anticoagulation reversal
– Warfarin
– Dabigatran
– Rivaroxaban, Apixaban, Edoxaban
• Anticoagulation measurement
30
Case
• 78 yo female with AF, HTN, and peripheral vascular disease
• Admitted with moderate cellulitis and dry gangrene
• Will need BKA in next few days
• On dabigatran (Pradaxa), CrCl = 40 ml/min
• What would you do?
A. Hold dabigatran for 2 days prior to surgery
B. Hold dabigatran for 4 days prior to surgery
C. Hold dabigatran for 4 days prior to surgery and bridge with LMWH
D. Give idarucizumab (Praxbind) and go to surgery now
E. Measure aPTT daily and go to surgery when normal
1/18/2016
16
31
Spyropoulos AC, Douketis JD. Blood. 2012 Oct 11;120(15):2954-62. PMID: 22932800
32
Post hoc Analysis of RELY Trial
• Randomized open label comparison of dabigatran vs. warfarin in AF
• Bridging defined as LMWH or heparin
• Prophylactic doses
• Intermediate doses
• Therapeutic doses
• Proportion of patients bridged
• Warfarin 27.5%
• Dabigatran 15.4%
Douketis JD. Thromb Haemost. 2015 Mar;113(3):625-32. PMID: 25472710
1/18/2016
17
33
Post hoc Analysis of RELY Trial
Douketis JD. Thromb Haemost. 2015 Mar;113(3):625-32. PMID: 25472710
34
Perioperative Management of Dabigatran
• Cohort study of 541 cases (97% AF) using standard protocol
• Approximately 80% adherence to protocol
• Major bleed (ISTH surgical): 1.8% [95% CI (0.7 – 3.0)]
• 1 TIA
Schulman S. Circulation. 2015 Jul 21;132(3):167-73. PMID: 25966905
1/18/2016
18
35 Residual Anticoagulation Effect of Pre-op Dabigatran
Douketis JD. J Thromb Haemost. 2015 Oct 29. PMID: 26512880
36
RE-VERSE AD Study
• 39 patients in procedure group
• 36 underwent a procedure
• 33 with normal hemostasis
• 2 mild abnormal hemostasis
• 1 moderate abnormal hemostasis
• Primary outcome: reversal at 4 hours
• 93% with dilute thrombin time
• 88% with ecarin clotting time
Pollack CV Jr. N Engl J Med. 2015 Aug 6;373(6):511-20. PMID: 26095746
88% - 93% reversal at 4 hours
1/18/2016
19
37
RE-VERSE AD Study
• Thrombotic complications of all 90 patients post idarucizumab
• No patient was receiving anticoagulation
Pollack CV Jr. N Engl J Med. 2015 Aug 6;373(6):511-20. PMID: 26095746
Thrombotic event Time after idarucizumab
DVT and PE 2 days
DVT 7 days
DVT, PE and left atrial thrombus 9 days
NSTMI 13 days
Ischemic stroke 26 days
38
Protocol to Reverse Dabigatran with Idarucizumab
Eikelboom JW. Circulation. 2015 Dec 22;132(25):2412-22. PMID: 26700008
1/18/2016
20
PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION
• Bridging anticoagulation
– Mechanical valves
– Atrial fibrillation
– Venous thromboembolism
• Anticoagulation reversal
– Warfarin
– Dabigatran
– Rivaroxaban, Apixaban, Edoxaban
• Anticoagulation measurement
40
Sie
gal
DM
. J T
hrom
bT
hrom
boly
sis.
20
15 J
an 1
4. P
MID
: 2
558
6208
1/18/2016
21
41
Systematic Review of Factor VIIa RCTs
Levi M. N Engl J Med. 2010 Nov 4;363(19):1791-800. PMID: 21047223
42 Systematic Review of Non-Activated PCC Cohort Studies
Dentali F. Thromb Haemost. 2011 Sep;106(3):429-38. PMID: 21800002
1/18/2016
22
43
Andexanet Alpha
• Short duration of action
• Will require bolus + infusion
• Dose different for apixaban and rivaroxaban
• ANNEXA 4 study
• only bleeding, not urgent surgery
Siegal DM. N Engl J Med. 2015 Dec 17;373(25):2413-24. PMID: 26559317
PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION
• Bridging anticoagulation
– Mechanical valves
– Atrial fibrillation
– Venous thromboembolism
• Anticoagulation reversal
– Warfarin
– Dabigatran
– Rivaroxaban, Apixaban, Edoxaban
• Anticoagulation measurement
1/18/2016
23
45
Lab Testing of DOACs
Blann AD. J Am Coll Cardiol. 2014 Sep 16;64(11):1140-2. PubMed PMID: 25212649
PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION
• Bridging anticoagulation
– Mechanical valves
– Atrial fibrillation
– Venous thromboembolism
• Anticoagulation reversal
– Warfarin
– Dabigatran
– Rivaroxaban, Apixaban, Edoxaban
• Anticoagulation measurement